• Welcome Guest
  • View Cart
  • Phone (US): 703.778.3080
  • 0Shopping Cart
  • Market Reports
  • Market Research Subscriptions
    • Knowledge Center
  • Custom Market Research
    • Quantitative Market Research
    • Qualitative Market Research
    • RateMyProduct
  • Blog
  • Featured
    • Free Downloads
    • View Webinars On-Demand
    • The IVD Market in 2023: $130 Billion and Growing
    • The Point of Care Testing Market
    • Immunoassays
  • About Us
    • Contact
  • Search
  • Menu Menu
  • Biotechnology
    • Next Generation Sequencing
    • Proteomics
    • Biopharmaceuticals
    • Instrumentation & Equipment
    • Emerging Technologies
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
    • Over-the-Counter
    • Drug Discovery
    • Cancer Treatment
    • Manufacturing & Packaging
    • Prescription Drugs
  • Diagnostics
    • Molecular Assays
    • Point-of-Care
    • Immunoassays
    • Infectious Disease
    • Clinical Chemistry
    • Oncology & Hematology
    • Lab Testing Services
    • Medical Imaging
  • Healthcare
    • Information Technology
    • Facilities & Settings
    • Insurance & Managed Care
  • Medical Devices
    • Wound Care
    • Drug Delivery
    • Equipment
    • Surgical
  • Login
Sale!
Awaiting product image

Filter your search

Search Report Keyword
Price
CATEGORIES
  • Biotechnology Market Research
  • cell and gene therapy
  • cell therapy
  • Diagnostics Market Research
  • gene therapy
  • Healthcare Information Technology
  • Healthcare Market Research
  • in vitro diagnostic
  • IVD
  • life sciences
  • Medical Devices Market Research
  • Molecular & Nucleic Acid Testing
  • Pharmaceuticals Market Research
  • Point-of-Care Diagnostics
  • sciences
  • vaccines

Knowledge Center Sidebar

Most Popular Research

  • Cell and Gene Therapy Business Outlook
  • The Worldwide Market for In Vitro Diagnostic Tests, 14th Edition
  • Clinical Diagnostics MasterFile
  • The Global Market for Medical Devices, 11th Edition
  • The World Market for Molecular Diagnostics Tests, 10th Edition
  • Remote Patient Monitoring and Telehealth Markets, 12th Edition

Next-Generation Sequencing Trends: Kalorama Survey of Laboratories

$3,600.00 – $7,200.00

Clear
SKU: KLI15538606 Categories: Biotechnology Market Research, Next Generation Sequencing Pages: 100
  • Description
  • Table of Contents
  • Latest reports

Description

Next-Generation Sequencing Trends: Kalorama Survey of Laboratories

Next-Generation Sequencing Trends: Kalorama Survey of Laboratories identifies some of the key changes taking place with both next-generation sequencing (NGS) systems in relation to their usage in labs and in relation to the sequencing of clinical samples for diagnostic or clinical research purposes. The report surveys the following aspects of NGS systems: system installations; sequencer applications, clinical applications, and usage trends; preferences and evaluations; and future purchase plans.

This survey – of 78 laboratories, carried out from August to October of 2017 – reached a mix of labs, providing both a range of industry segments as well as groups of labs with both next-generation and capillary systems.

The survey presents results in terms of the types of systems installed by model, by region, by industry, and by lab function.

Responses related to labs’ usage of sequencers in terms of the applications and sample types for which they are run are also provided. Other areas covered include outsourcing and future expectations. The survey also provides segmentation of the applications expected to increase, by brand of next-generation system owned.

The survey gives labs’ feedback with regard to the most important criteria for sequencer purchase, including cost of system, cost per sample or run, raw accuracy, ease of use, and other factors. Further, the survey provides this information with respect to the brand or type of sequencer system owned.

Finally, the survey provides responses related to labs’ plans to for future purchase of sequencers.

Table of Contents

1: EXECUTIVE SUMMARY

SCOPE

METHODOLOGY

OUTLINE

2: SURVEY DEMOGRAPHICS

REGIONAL DISTRIBUTION OF RESPONDENTS’ LABS

Table 2-1: Survey Respondents by Region (USA, ROW, Europe, Total)

Figure 2-1: Survey Respondents by Region

Figure 2-2: World Distribution of Survey Respondents

INDUSTRIAL DISTRIBUTION OF RESPONDENTS’ LABS

Figure 2-3: Primary Industry/ Segment Labs Belong To

LABORATORY FUNCTION OF RESPONDENTS’ LABS

Figure 2-4: Respondents by Function (Research, Service provider (external), Core lab / shared facility, Diagnostic services / products)

DISTRIBUTION BY NUMBER OF SEQUENCERS

Total Numbers of Systems in Labs

Figure 2-5: Distribution by Sequencers in Lab

Numbers of 2nd- and 3rd Generation Systems

Figure 2-6: Number of Next-Generation Sequencers in Labs

Remaining Non-NGS / Capillary Systems

Figure 2-7: Number of Non-NGS / Capillary Sequencers in Labs

BRAND(S) / TYPES(S) OF SEQUENCERS OWNED

Table 2-2: Brands / Types of Sequencers Owned by All Respondents

Table 2-3: Number of a Given Brand / Type in Labs Owning Type, 2017

Average Number of a Given Sequencer in Labs

Table 2-4: Average Number of a Given Sequencer in Labs Owning Type, 2013

POSITION/ ROLE OF RESPONDENTS

Figure 2-8: Distribution of the Respondents’ Positions in the Labs or Organizations (Lab technician, VP or exec. Management,

Professor/PI, Genetic counselor, Lab manager/director, Research assoc./scientist)

3: SYSTEM INSTALLATIONS

DISTRIBUTION OF SEQUENCER MODELS

Next-Generation Sequencing Trends: Kalorama Survey of Laboratories

Overall Totals

Table 3-1: Sequencer Models in Respondents’ Labs

Installed Base by System Owned

Table 3-2: Installed Base of Labs, by System(s) Owned (# of Systems)

Table 3-3: Installed Base of Labs, by System(s) Owned (% of Systems)

Table 3-4: Cross-Ownership of Sequencing Systems Trend

Table 3-5: Installed Base of Labs, by System(s) Owned (% of Systems)

DISTRIBUTION OF NUMBER OF SEQUENCERS

Table 3-6: Number of Systems in Labs Segmented across Two Dimensions – Number of Next-Generation Systems and Number of Non-

NGS / Capillary Systems

INSTALLED BASE BY REGION

Overall Brand/ Type

Table 3-7: Distribution of Systems by Region (USA, Europe, ROW, Overall)

Table 3-8: Sequencer Models in Respondents’ Labs, by Region (% of Systems; USA, Europe, ROW, Overall)

NEXT-GENERATION SYSTEMS

Table 3-9: NGS Models in Respondents’ Labs, by Region by Percent of Systems (USA, Europe, ROW, Total)

NON-NGS / CAPILLARY SYSTEMS

Table 3-10: Non-NGS / Capillary Systems Models by Region (USA, Europe, ROW, Overall)

INSTALLED BASE BY INDUSTRY SEGMENT

Overall Brand/ Type

Table 3-11: Number of Systems Installed, by Industry / Segment(s)

Brand / Type of Sequencer Systems Installed, by Industry/ Segment, 2017

Table 3-12: Brand / Type of Sequencer Systems Installed, by Industry/ Segment, 2017 (% of Systems)

Comparison to 2013

Table 3-13: Brand / Type of Sequencer Systems Installed, by Industry/ Segment, 2013 (% of Systems)

INSTALLED BASE OF NEXT-GENERATION SYSTEMS

Table 3-14: Installed Base of Next-Generation Systems, Segmented by Industry (Academia, University; Hospital, Medical Center; Independent Reference Lab; Contract Research/ Svcs; Independent Rsch/ Nonprofit; Biotech/ Diagnostics/ Vaccines; Government; Overall)

Table 3-15: Next-Generation Models in Respondents’ Labs, by Industry/ Segment (% of Labs Owning Given Systems) (Academia, University; Hospital, Medical Center; Independent Reference Lab; Contract Research/ Svcs; Independent Rsch/ Nonprofit; Biotech/ Diagnostics/ Vaccines; Government)

Table 3-16: Next-Generation Models in Respondents’ Labs, by Industry/ Segment (% of Total Respondents’ Systems)

INSTALLED BASE BY LABORATORY FUNCTION

Overall Brand/ Type by Laboratory Function

Table 3-17: NGS Models in Respondents’ Labs, by Lab Function (% of Systems) (Research, Service provider (external), Core lab/ shared facility, Diagnostic services/ products)

Brand / Type of Sequencer System Installed, by Lab Function

Next-Generation Sequencing Trends: Kalorama Survey of Laboratories

Table 3-18: Brand / Type of Sequencer System Installed, by Lab Function (% of Systems; Research, Service provider (external), Core lab/ shared facility, Diagnostic services/ products)

NEXT-GENERATION SYSTEMS

Table 3-19: NGS Models in Respondents’ Labs, by Lab Function (% of Labs Owning Given NGS System) (Research, Service provider (external), Core lab/ shared facility, Diagnostic services/ products)

Table 3-20: NGS Models in Respondents’ Labs, by Lab Function (% of All Respondent Systems) (Research, Service provider (external), Core lab/ shared facility, Diagnostic services/ products, Overall)

Figure 3-1: Sequencers per Lab, Average, by Lab Function (Overall; Diagnostic services/ products; Core lab/ shared facility; Service provider (external); Research)

4: SEQUENCER APPLICATIONS, CLINICAL APPLICATIONS, AND USAGE TRENDS

SEQUENCER APPLICATIONS AND USAGE

Applications Run, Overall and by Brand/ Type

Table 4-1: NGS Application Volume by Model (% of Sequencing)

Figure 4-1: Applications by Sequencer Model

LIKELY INCREASES IN APPLICATIONS AND VOLUME

Overall

Table 4-2: Applications Expected to Increase the Most (Resequencing/ amplicon; RNA seq, transcriptomics, gene expr.; Metagenomics; De novo sequencing & whole genome; Exome; Methylation, other epigenetics; ChIP-seq; Small RNA, micro RNA; Expect mostly remain the same)

Figure 4-2: Applications Expected to Increase the Most (Resequencing/ amplicon; RNA seq, transcriptomics, gene expr.; Metagenomics; De novo sequencing & whole genome; Exome; Methylation, other epigenetics; ChIP-seq; Small RNA, micro RNA; Expect mostly remain the same)

Applications Expected to Increase the Most Overall

BY BRAND OF NEXT-GENERATION SYSTEM OWNED

Table 4-3: Applications Expected to Increase, Illumina Owners (Resequencing/ targeted; mRNA-seq / transcriptome; de novo/ whole genome; Metagenomics; Exome; Methylation, other epigenetics; Small/ micro RNA; ChIP-seq)

Table 4-4: Applications Expected to Increase, Pac Bio Owners (Resequencing/ targeted; mRNA-seq / transcriptome; de novo/ whole genome; Metagenomics; Exome; Methylation, other epigenetics; Small/ micro RNA; ChIP-seq)

Table 4-5: Applications Expected to Increase, Thermo Owners (Resequencing/ targeted; mRNA-seq / transcriptome; de novo/ whole genome; Metagenomics; Exome; Methylation, other epigenetics; Small/ micro RNA; ChIP-seq)

Table 4-6: Applications Expected to Increase, Non-NGS / Capillary Owners (Resequencing/ targeted; mRNA-seq / transcriptome; de novo/ whole genome; Metagenomics; Exome; Methylation, other epigenetics; Small/ micro RNA; ChIP-seq)

Table 4-7: Applications Expected to Increase, All Users (Resequencing/ targeted; mRNA-seq / transcriptome; de novo/ whole genome; Metagenomics; Exome; Methylation, other epigenetics; Small/ micro RNA; ChIP-seq)

APPLICATIONS EXPECTED TO INCREASE, BY NGS BRAND OWNED (% OF LABS)

Growth in Sequencing, NGS vs Non-NGS / Capillary Systems

Table 4-8: Expected Growth in Sequencing Volume (% of Labs)

Next-Generation Sequencing Trends: Kalorama Survey of Laboratories

CAPACITY USAGE OF SYSTEMS

Figure 4-3: Avg. Percentage of Systems’ Capacity Used, by Brand

Percentage of Systems’ Capacity Used, by Brand

OUTSOURCING

Table 4-9: Percentage of Sequencing Volume Outsourced

Percentage of Sequencing Volume Outsourced

Table 4-10: Percentage of Sequencing Volume Outsourced, by Region (N. America, Europe, ROW, Overall)

Table 4-11: Reason for Outsourcing

CLINICAL APPLICATIONS

Sequencing of CLIA Regulated Patient Samples

Table 4-12: How Labs Address Sequencing of Regulated Patient Samples (# of Labs)

HOW LABS ADDRESS SEQUENCING OF REGULATED PATIENT SAMPLES

Certification for Regulated Samples

Table 4-13: Labs’ Certification for Regulated Patient Samples

Change in Regulated Samples vs. Non-Regulated Samples

Table 4-14: Distribution of Samples, Est. 2017 (% of Labs)

Table 4-15: Distribution of Samples, Expected 2018 (% of Labs)

Certified Labs

Table 4-16: Volume of Regulated vs. Non-Regulated Samples at Certified Labs, Est. 2017 and Expected 2018 (% of Sequencing; Sample type: Non patient/ human samples; Non CLIA patient/ human sample; CLIA patient samples)

Table 4-17: Volume of Regulated vs. Non-Regulated Samples at Non-Certified Labs, Est. 2017 and Expected 2018 (% of Sequencing; Sample type: Non patient/ human samples; Non CLIA patient/ human sample; CLIA patient samples)

Table 4-18: Distribution of Samples, Est. 2017 (% of Labs) (Non patient/ human samples; Non CLIA patient/ human samples; CLIA patient samples)

Table 4-19: Distribution of Samples, Expected 2018 (% of Labs) (Non patient/ human samples; Non CLIA patient/ human samples; CLIA patient samples)

SEQUENCERS USED OR PLANNED FOR PATIENT/ HUMAN SAMPLES

Regulated Patient/ Human Samples

Table 4-20: Sequencers Most Likely to Be Used for Regulated Patient Samples

Figure 4-4: Sequencers Used for Regulated Patient Samples (% of Systems)

Sequencers Used for Regulated Patient Samples

Table 4-21: Sequencers Likely to Be Used for Regulated Patient Samples (% of Labs)

Figure 4-5: Sequencers Likely to Be Used for Regulated Patient Samples (% of Labs)

DISEASE/ THERAPEUTIC AREAS WHERE SEQUENCING APPLIED

Regulated Patient/ Human Samples

Table 4-22: Regulated Patient/ Human Samples (Rare inherited/ genetic, Cancer, Prenatal, Infectious, Pharmacogenetic, Hematological, Healthy ind’ls)

Table 4-23: Remaining Capillary Systems, How Used (Rare inherited/ genetic, Cancer, Prenatal, Infectious, Pharmacogenetic, Hematological, Healthy individuals)

Next-Generation Sequencing Trends: Kalorama Survey of Laboratories

Non-Regulated Patient/ Human Samples

Table 4-24: Disease Areas Where Sequencing Applied (% of Volume) (Rare inherited/ genetic; Cancer; Pharmacogenetic; Infectious; Autoimmune/ immunology; Neurology; HLA/ MHC/ transplantation; Healthy individuals; Other; Varies, large range)

Table 4-25: Remaining Capillary Systems, Where Used in Non-Regulated Samples (Rare inherited/ genetic; Cancer; Pharmacogenetic; Infectious; Autoimmune/ immunology; Neurology; HLA/ MHC/ transplantation; Healthy individuals; Other; Varies, large range)

Disease Areas Expected to Grow Fastest

Table 4-26: Regulated Sequencing Expected to Grow Fastest (% of Labs) (Rare genetic/ inherited diseases, Cancer, Pharmacogenetics, Infectious, Prenatal)

Table 4-27: Non-Regulated Patient/ Human Sequencing Expected to Grow Fastest Non-CLIA (Cancer, Inherited diseases, Infec./ immunology/ autoimmune, Neurology, Pharmacogenetics, HLA/ MHC/ transplantation, Cardiovascular)

Challenges for Growth of Clinical Sequencing

Table 4-28: Challenges for Growth of Clinical Sequencing

5: PREFERENCES AND EVALUATIONS

KEY CRITERIA FOR CHOOSING SEQUENCERS

Overall

Table 5-1: Most Important Criteria for Sequencer Purchase (cost of system, cost per sample or run, raw accuracy, ease of use user friendliness, flexibility range of apps, throughput, vendor cust svc, specific apps needs, compatibility precedence, software IT, turnaround run time, read length, other)

MOST IMPORTANT CRITERIA FOR SEQUENCER PURCHASE

By System

Table 5-2: Most Important Criteria for Purchases, Illumina Owners (cost of system, cost per sample or run, raw accuracy, ease of use user friendliness, flexibility range of apps, throughput, vendor cust svc, specific apps needs, compatibility precedence, software it, turnaround run time, read length, Other)

Table 5-3: Most Important Criteria for Purchases, Pac Bio Owners (cost of system, cost per sample or run, raw accuracy, ease of use user friendliness, flexibility range of apps, throughput, vendor cust svc, specific apps needs, compatibility precedence, software it, turnaround run time, read length, Other)

Table 5-4: Most Important Criteria for Purchase, Thermo Fisher Owners (cost of system, cost per sample or run, raw accuracy, ease of use user friendliness, flexibility range of apps, throughput, vendor cust svc, specific apps needs, compatibility precedence, software it, turnaround run time, read length, Other)

Table 5-5: Most Important Criteria for Purchase, Capillary Owners (cost of system, cost per sample or run, raw accuracy, ease of use user friendliness, flexibility range of apps, throughput, vendor cust svc, specific apps needs, compatibility precedence, software it, turnaround run time, read length, Other)

Table 5-6: Most Important Criteria for Purchase, Overall NGS Owners (cost of system, cost per sample or run, raw accuracy, ease of use user friendliness, flexibility range of apps, throughput, vendor cust svc, specific apps needs, compatibility precedence, software it, turnaround run time, read length, Other)

EVALUATIONS OF SEQUENCERS

Illumina -Comments

Oxford Nanopore -Comments

Pacific Biosciences -Comments

Next-Generation Sequencing Trends: Kalorama Survey of Laboratories

CHANGES OR IMPROVEMENTS

Table 5-7: Feature Most Wanted to Change or Improve (Lower sequencing cost, Cheaper libr prep, Automate/ shorten library prep, Longer reads, Robustness/ reliability of systems, Improve/ simplify data analysis, Choice of fewer lanes per run, Enable tracking barcodes etc, Flexibility for diff apps, Better customer support, Shorter run time, More flexible/ adaptable software)

BOTTLENECKS IN PROCESS

Table 5-8: Bottlenecks (Data analysis/ interpretation, Sequencer run time, Library preparation, Reporting, Waiting to fill flow cells)

6: FUTURE PURCHASE PLANS

TIME FRAME OF PURCHASE PLANS

Overall

Table 6-1: Time Frame for Future Purchase (0-6 months, 7-12 months, 1-2 years, Planned but uncertain time frame, No plan)

Figure 6-1: Time Frame of the Purchases Planned (0-6 months, 7-12 months, 1-2 years, Planned but uncertain time frame, No plan)

By Brand/ Type Owned

Table 6-2: Time Frame for Future Purchase, by Brand Owned (# of Labs) (0-6 months, 7-12 months, 1-2 years, Planned but uncertain time frame, No plan)

By Laboratory Function

Table 6-3: Time Frame for Future Purchase by Type of Lab (Overall, Research, Service provider (ext), Core lab/ shared, Diagnostic svcs/ prod) (0-6 months, 7-12 months, 1-2 years, Planned but uncertain time frame, No plan)

Purchase Plan Time Frame by Region

Table 6-4: Time Frame for Future Purchase, by Region (% of Labs) (USA, Europe, ROW) (0-6 months, 7-12 months, 1-2 years, Planned but uncertain time frame, No plan)

SYSTEMS LIKELY TO BE CONSIDERED FOR PURCHASE

Overall

Table 6-5: Sequencer Models Likely to Be Considered

Sequencer Models Likely to Be Considered

Purchase Decision Preference by Brand/ Type Owned

Table 6-6: Sequencer Models Likely to Be Considered, by Brand/Type Owned (% of Labs)

By Industry / Segment

Table 6-7: Sequencer Models Likely to Be Considered, by Industry/Segment Owned (% of Labs)

By Laboratory Function

Table 6-8: Sequencer Models Likely to Be Considered, by Lab Function (% of Labs) (Research, Service provider (ext), Core lab, Diagnostics/ clinical, Overall)

By Region

Table 6-9: Sequencer Models Likely to Be Considered, by Region (% of Labs) (USA, Europe, ROW, Overall)

    The Worldwide Market for Mass Spectrometry in Clinical Labs, 2024
    September 11, 2024
    Worldwide Sequencer Market, 2023-2028
    August 8, 2024
    The Worldwide Market for Liquid Biopsy, 6th Edition
    December 29, 2023
    The Market for RNA Sequencing, 3rd Edition
    September 8, 2023

Related products

  • Placeholder image

    Molecular Nanotechnology in Medicine: A Market Briefing

    $895.00 – $1,790.00
  • Placeholder image

    Worldwide Market for Orthopedic Biomaterials, The

    $2,625.00 – $5,250.00
  • Placeholder image

    Mass Spectrometry in Protein Biomarker Applications – Software, Services, and Instrument Markets

    $995.00 – $5,990.00
  • Placeholder image

    Immunomodulators in Cancer Therapy: Emerging Products and Markets

    $3,500.00 – $7,000.00

Contact Us

  • 671 North Glebe Road, Suite 1610 Arlington, VA 22203 United States

  • Email Us

  • 703-778-3080

  • Send us a message!

Pay Invoice

  • Pay an Invoice by Credit Card

Follow Us!

Latest Blogs

  • 4 Fascinating Facts About Cancer Diagnostics March 4, 2025
  • Food Animal Diagnostics Market: Spotlight on Disease Testing Amid Bird Flu Surge February 20, 2025
  • Custom Competitive Intelligence (CI) Research: A New Strategic Imperative For Lab Diagnostics Companies  February 19, 2025
  • The Rise of Pharmacodiagnostics in the $10 Billion Global Cancer Diagnostics Market February 1, 2025
  • IVD Trends to Watch: Personalized Medicine Adds Precision to Diagnostic Testing January 2, 2025

Sitemap

  • Home
  • About
  • Blog
  • Contact
  • Sitemap

Your Data and Privacy

  • View our Privacy Policy
  • GDPR Statement
  • Privacy Settings

About Us

Kalorama Information, part of Science and Medicine Group, has been a leading publisher of market research in medical markets, including the biotechnology, diagnostics, medical device, and pharmaceutical industries for more than 30 years. Our comprehensive, timely, quality research and innovative approach to analysis and presentation of market intelligence have made Kalorama Information a premier source of market information for top industry decision makers.

Visit Science and Medicine Group
Biosimilars: Global Market, Trends and Competitor AnalysisBiopharmaceutical Contract Manufacturing (BCMO) Market – by Type of Service,...
Scroll to top